Incyte, a company that makes medicines, had a good last quarter, selling more than expected. But, their predictions for how much they will sell in the future were lower than what experts thought. This news made the company's stock price go down.
- Incyte's sales were up 16% from last year.
- Two of their main medicines, Jakafi and Opzelura, sold very well.
- However, they didn't predict as much future sales as experts hoped.
| Medicine | 2025 Sales Prediction (Incyte) | 2025 Sales Prediction (Experts) |
|---|---|---|
| Jakafi | $2.925 billion - $2.975 billion | $3.34 billion |
| Opzelura | $630 million - $670 million | $672.2 million |
